Research Expert: Sarah Overall
  • Published: Jul 2025
  • Pages: 150
  • SKU: IRTNTR77089

  • Latest News- Low-Concentration Atropine Market: Atropine sulfate 0.01 percentage is expected to lead the Type segment during 2024-2028

    The Low-Concentration Atropine Market is being driven by Increasing prevalence of myopia

    The Low-Concentration Atropine Market is expected to grow at a CAGR of 18.81% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 1039.97 million. In the global low-concentration atropine market, vendors are prioritizing research and development (R&D) to create innovative therapies for myopia treatment. Pharmaceutical and biopharmaceutical companies are increasing their R&D investments, fostering the advancement of eye disease treatments. Notably, Vyluma's CHAMP (Childhood Atropine for Myopia Progression) Study, which assessed the efficacy of NVK002, a low-dose atropine solution, in the second stage of Phase III, was recently completed in October 2023. The New Drug Application (NDA) for NVK002 is currently under FDA review, with a decision anticipated in January 2024. 

    Get more information on Low-Concentration Atropine Market by requesting a sample report

    Which Factors Are Causing a Surge in Market Growth?

    The market is segmented based on

    • Type
      • Atropine sulfate 0.01 percentage
      • Atropine sulfate 0.025 percentage
      • Atropine sulfate 0.05 percentage
    • Application
      • Child
      • Adult
    • Geography
      • Asia
        • China
        • Japan
      • North America
        • Canada
        • US
      • Europe
        • Germany
      • Rest of World (ROW)

      According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

      • Increasing prevalence of myopia
      • Rising awareness regarding vision care
      • Growing demand for vision correction among aging population

      However, the market also witnesses some limitations, which are as follows:

      • Side effects and uncertainty in efficacy of low-concentration atropine
      • Shortage of skilled ophthalmologists
      • High cost of myopia treatment

      Benefits of Buying Global Low-Concentration Atropine Market Research Report by Technavio

      Rich Experience: 20+ years leading global market research, trusted insights across industries.

      Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

      Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

      Market Scope in Low-Concentration Atropine Market Research Report

      Market Scope

      Report Coverage

      Details

      Page number

      155

      Base year

      2023

      Historic period

      2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 18.81%

      Market growth 2024-2028

      USD 1039.97 million

      Market structure

      fragmentation

      YoY growth 2023-2024(%)

      11.27

      Key countries

      US, Canada, Germany, China, and Japan

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Find out which segment is leading the market by accessing the free PDF report

      Research Analysis Overview

      The Low-Concentration Atropine market encompasses the use of Atropine Sulfate as a mydriatic and cycloplegic agent in ophthalmic applications. In pediatric and adult ophthalmology, low dose Atropine is employed for various purposes such as refractive error correction, amblyopia treatment, strabismus management, retinal examination, contact lens fitting, and ophthalmological surgery. The therapeutic index of Atropine is crucial for safe and effective use, influencing drug metabolism, elimination, plasma concentration, and ocular penetration. Therapeutic monitoring, clinical endpoint assessment, safety evaluation, quality control, ocular irritation, allergic reactions, patient selection, dosage regimen, and medication adherence are essential considerations in the use of this ophthalmic drug.

      Market Research Overview

      The low-concentration atropine market is a segment of the larger global pharmaceuticals market, which is a key component of the healthcare industry. According to Technavio, the global pharmaceuticals market, encompassing entities involved in R&D and manufacturing of various drug types, including generic and non-generic, was valued at USD1,495.51 billion in 2023. Factors driving the growth of this market include an aging population leading to increased demand for healthcare and pharmaceuticals, as well as advancements in drug research and development. Specifically within the low-concentration atropine market, the drug's ocular accommodation effects, including mydriasis and cycloplegia, contribute to improved refraction accuracy and intraocular pressure management in various ophthalmic applications.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.


      Contacts

      Technavio Research
      Jesse Maida
      Media & Marketing Executive
      US: +1 844 364 1100
      UK: +44 203 893 3200
      Email: media@technavio.com
      Website: www.technavio.com/

      Read News Read Less
      Interested in this report?
      Get your sample now!

    Safe and Secure SSL Encrypted

    Technavio

    • 2500 USD

    [5 reports/month/user]

    • 5000 USD

    close
    • Basic Plan [5000 USD/Year]:

      Single User
      Download 5 Reports/Month
      View 100 Reports/Month
      Add upto 3 Users at 625 USD/user

    • Teams Plan [7500 USD/Year]:

      5 User
      Download 5 Reports/Month/User
      View 100 Reports/Month/User
      Add upto 30 Users at 500 USD/user

    *You can upgrade to Teams plan at Subscription page

    close
    • Single:

      One user only.
      Quick & easy download option

    • Enterprise:

      Unlimited user access (Within your organization).
      Complimentary Customization Included

    *For Enterprise license, go to checkout page

    Technavio Get the report (PDF) sent to your email within minutes.